About
About Kobayashi Pharmaceutical Co., Ltd
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
Research context
Kobayashi Pharmaceutical Co., Ltd appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 7 months ago
Kobayashi Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 1.7% below its 200 day moving average.
From a valuation standpoint, the stock is 95.2% cheaper than other stocks from the Consumer Defensive sector with a price to sales ratio of 5.4.
Kobayashi Pharmaceutical Co., Ltd's total revenue sank by 9.5% to $45B since the same quarter in the previous year.
Its net income has increased by 1.4% to $4B since the same quarter in the previous year.
Based on the above factors, Kobayashi Pharmaceutical Co., Ltd gets an overall score of 2/5.